Associated laboratories:
Cobra Laboratory – Organic Chemistry Team, Rouen , ICMUB P2DA team, Dijon
The production of imaging agents has been identified as a major obstacle to medical imaging research. Although some laboratories have the capacity to generate these agents for their own investigative work, they are not in a position to supply other centers. As a result, the aim of this workpackage is to provide a framework for the production of imaging agents for which there is no commercial supply, and to generate new generate new imaging probes or contrast agents for in vivo for in vivo biomedical research and clinical applications (e.g. optical agents, radionuclides, magnetic resonance agents, etc.).
The RE1 aims to stimulate interdisciplinarity in collaborative medical imaging projects, and accelerate the design, manufacture and eventual clinical use of new molecular imaging agents with greater sensitivity, selectivity and minimal toxicity.
RE1 is thus organized into 4 sub-modules:
WP1.1: Modular targeting platform for imaging
Development of synthetic macromolecules & marking techniques
WP1.2: development of probes and contrast agents
Introduction of short-lived radionuclides
Optimizing the binding properties of chelating agents (for applications in MRI, Optics, SPECT and PET)
Optimization of agents used in MRI and optical imaging
Development of innovative technologies including clickable, intelligent and multimodal probes
WP1.3: nanoparticles for imaging
– development of nanoparticles for multimodal imaging
– development of multifunctional nanoparticles with high specificity and detectability in imaging
WP1.4: Proof of concept, clinical applications, translational research
Scale up process: from the chemistry lab to production
- Proof of concept and preclinical and clinical trials